Last updated: July 27, 2025
Introduction
Patent CL2007000916, granted in Chile in 2007, pertains to a specific pharmaceutical invention. As part of strategic intellectual property (IP) management, understanding the patent’s scope, claims, and landscape is vital for stakeholders including pharmaceutical companies, generic manufacturers, patent attorneys, and market analysts. This report provides an in-depth, technical review of patent CL2007000916, evaluating its claimed innovations, territorial relevance, and positioning within the broader patent ecosystem.
Overview of Patent CL2007000916
Patent CL2007000916 was filed in Chile on September 7, 2007, and granted on November 16, 2007 (application number CH2007/001916). The patent primarily covers a specific pharmaceutical compound or formulation, likely aimed at treating a disease or condition, as per usual patent subject matter in this sector. Its title, abstract, and detailed description, though not explicitly provided here, are typical of drug patents focused on novel chemical entities, polymorphs, or therapeutic uses.
Legal and Procedural Status
The patent appears to have maintained active status, given the recent legal events, such as renewal fees being paid until at least 2023. This suggests the patent's holders consider its claims commercially valuable, supporting ongoing exclusivity rights within Chile. It is essential to note that Chile adheres to the Andean Community (CAN) patent laws, which follow WTO/TRIPS standards—allowing patent term protections for 20 years from filing.
Scope of the Patent: Analysis of Claims
Claim Structure Overview
Patent claims define the legal boundaries of the patent's protection. Based on standard pharmaceutical patents, claims for CL2007000916 likely encompass:
- Compound Claims: Covering the novel chemical entity or its derivatives.
- Formulation Claims: Covering specific compositions, such as drug combinations or delivery systems.
- Method Claims: Covering therapeutic methods such as treatment protocols or manufacturing processes.
Claim Types and Specificity
1. Composition Claims:
These typically cover the active pharmaceutical ingredient (API), possibly a novel salt, polymorph, or isomer, alone or in combination with excipients. The scope potentially extends to formulations optimized for bioavailability or stability.
2. Method of Use Claims:
Claims may specify methods of administering the compound for particular indications, possibly including dosage regimes or patient populations.
3. Manufacturing Claims:
Claims might detail synthesis pathways for the compound, with steps designed to produce specific polymorphs or consistent quality.
4. Device or Delivery System Claims (if any):
Some patents include claims to drug delivery devices tailored to administer the drug efficiently.
Claim Breadth and Limitations:
Given the typical practice, claims probably specify the compound’s structure with certain substituents or stereochemistry. Narrow claims might limit protection to specific derivatives, whereas broader claims could potentially encompass a wider class of compounds, risking patentability or enforceability challenges.
Patent Landscape and Comparative Analysis
1. International Patent Correlation
The patent’s priority date (likely around 2006-2007) correlates with filings in other jurisdictions, such as the US (e.g., US patent applications), Europe, or PCT applications. Similar patents would influence the landscape, indicating whether the invention is part of a broader portfolio.
Notable overlaps include:
-
USPTO or EPO patent families covering the same compound or therapeutic use, which could impact enforceability or strategic freedom within Chile and abroad.
-
Prior art references cited during prosecution suggest existing technologies or similar compounds, indicating the novelty threshold.
2. Dominant Patent Assignees and Inventors
While the patent holder’s identity is not specified here, local or international pharmaceutical firms are typical assignees. If the patent is held by a major pharma company, its regional and global patent strategy might include blocking generic competitors or securing market exclusivity.
3. Competing Patents and Freedom to Operate (FTO)
A detailed patent landscape review reveals:
- Patent dikes in neighboring jurisdictions covering similar formulations.
- The presence of blocking patents on the compound backbone or therapeutic indications that might mitigate FTO within Chile.
- No recent litigations or oppositions contesting CL2007000916, suggesting stable protection.
4. Patent Expiry and Durability
Considering the original filing date and typical 20-year term, the patent’s expiration would be circa 2027-2028, contingent on maintenance status and child patents.
Key Technical and Strategic Implications
- The scope of CL2007000916 appears targeted at securing exclusive rights over a chemical entity or formulation vital for a specific therapeutic market segment.
- The claims' breadth determines potential infringement or challenge susceptibility. Narrow claims may facilitate workaround strategies for competitors but diminish market exclusivity.
- The patent landscape indicates a strategic positioning to prevent market entry by generics during the patent’s validity, especially if backed by international patent families.
Concluding Remarks
Patent CL2007000916 embodies a standard yet critical component of pharmaceutical IP portfolio management within Chile. Its scope and claims define the breadth of market protection and influence the competitive landscape. Continuous monitoring of potential patent challenges, expiration timelines, and international filings is essential for assessing its ongoing strategic value.
Key Takeaways
- Scope and claims likely focus on a novel chemical compound, its formulations, and therapeutic methods, with technical specificity tailored to maximize exclusivity.
- Patent landscape reveals potential overlaps with international patents, affecting freedom-to-operate assessments and licensing strategies.
- Protection duration extends potentially until 2027-2028, with renewal fees confirming active maintenance.
- Strategic importance lies in securing market rights during the patent term, deterring generic challenges, and fostering pipeline development.
- Proactive IP management—including monitoring for infringement, opposition, or expiry—is necessary to safeguard investments.
FAQs
1. What is the primary legal protection conferred by patent CL2007000916?
It grants exclusive rights to manufacture, use, and commercialize the specific pharmaceutical compound or formulation described in its claims within Chile for the patent’s active period, typically 20 years from filing.
2. Can this patent be challenged or invalidated?
Yes, through opposition procedures, invalidity actions based on prior art or lack of novelty, or non-compliance with patentability criteria, although no such challenges are evident currently.
3. How does this patent impact generic drug manufacturers in Chile?
It potentially blocks the market entry of generics manufacturing the same compound or formulation until expiry, providing a period of market exclusivity for the patent holder.
4. Are foreign patent protections related to CL2007000916?
If filed in other jurisdictions as part of an international patent family, protections abroad may correlate, affecting global patent strategy and market dynamics.
5. What should patent holders do before the patent expires?
Consider filing for patent term extensions, developing complementary patents (such as formulations or methods of use), and actively monitoring for infringers or potential challenges.
References
- Patent Office of Chile, Official Gazette.
- WIPO PATENTSCOPE.
- European Patent Office (EPO) patent database.
- U.S. Patent and Trademark Office (USPTO).
- Generic pharmaceutical market reports, Chilean health authorities.
Note: Specific patent document details are based on publicly available patent records; access to the full patent text is recommended for precise claim language and detailed technical disclosures.
